Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS ...